India's metabolic therapy market is undergoing a structural shift following the patent expiry of semaglutide, triggering a rapid transition from a premium, innovator-led market to a highly competitive, volume-driven segment. According to reports from The Economic Times, the category is now witnessing a sharp inflection in demand, supported by significant price erosion of nearly 85–90% and a surge in product launches. The addressable opportunity remains substantial with an estimated 75–80 million obese individuals and a large proportion suffering from co-morbid conditions, making the need for structured obesity management increasingly evident.
Over the next 3–5 years, the market could scale to ₹34–67 billion, driven by rising patient adoption and chronic therapy demand, as reported by The Economic Times. The expanding prescriber base is a key growth driver, with adoption increasingly supported by cardiologists, gastroenterologists, gynaecologists, and other specialists due to the multi-system impact of obesity and metabolic disorders. However, the sector faces structural challenges with the entry of over 10–15 players intensifying competition and leading to rapid market fragmentation, where individual revenue gains are likely to remain modest with low single-digit contribution to overall sales for most participants.
According to The Economic Times, Ajanta Pharma is preparing to launch generic semaglutide post patent expiry of Novo Nordisk's Ozempic/Wegovy in India, while continuing to expand its portfolio in high-growth segments such as dermatology, pain management, and nephrology. Management expects mid-teens revenue growth with EBITDA margins around 27%, supported by expansion in Asia and Africa, a strong US product pipeline, and strategic addition of medical representatives to drive execution. The company's long-term growth is driven by its expanding presence in branded generics across India, US, Africa, and Asia with a focus on chronic therapies.
As reported by The Economic Times, Sun Pharma's Innovation momentum remains a key growth pillar, with specialty and novel therapies scaling up meaningfully. The company delivered in-line adjusted revenues and EBITDA 6% ahead of estimates in 3QFY26, supported by robust domestic formulation growth and favorable mix. USD 1 billion+ innovative sales (ex-milestones) provide resilience against US pricing pressure, while strong domestic formulation execution and consistent market share gains underpin diversified, sustainable growth drivers. Management estimates EM+ROW revenues to reach ₹230 billion over FY25-28 at 12% CAGR.
According to The Economic Times, pricing dynamics reflect a clear stratification with premium, mid-tier, and mass-market strategies co-existing, while emerging structural trends show rising preference for next-generation therapies. The combination of pricing pressure, intense competition, and limited differentiation suggests that value capture may remain constrained, making scale and execution critical in navigating this evolving landscape. Despite challenges, the GLP-1 segment in India presents a compelling volume-led growth opportunity underpinned by strong demand fundamentals, though the sector faces ongoing pricing pressures and commoditisation concerns.
